Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Abstract Text:

Roland Schnell,Markus Dietlein,Klaus Schomäcker,Carsten Kobe,Peter Borchmann,Harald Schicha,Michael Hallek,Andreas Engert,

BACKGROUND: Radioimmunotherapeutics directed against CD20 have been established in several types of B-cell non-Hodgkin's lymphoma (NHL). Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) is the only approved radio - immunoconstruct for NHL in the EU. The malignant Hodgkin's and Reed-Sternberg cells in classical Hodgkin's lymphoma (cHL) express CD20 infrequently. Thus, only very limited data of cHL patients treated with anti- CD20 immunoconstructs are available. To date, none of the patients treated with 90Y ibritumomab tiuxetan demonstrated any response. CASE REPORT: We report on a 78-year-old female patient suffering from a second systemic relapse of classical nodular lymphocyte-rich HL who experienced a complete remission (CR) after treatment with 90Y ibritumomab tiuxetan lasting over a period of 6 months. DISCUSSION: Treatment of patients with cHL with the anti-CD20 monoclonal antibody rituximab resulted in a response rate of 22%. 90Y ibritumomab tiuxetan demonstrated superiority compared with rituximab in a randomized phase III trial. HL represents a radiosensitive tumor responding to anti-CD30 or antiferritin radioimmunotherapy. Further HL patients have to be treated with 90Y ibritumomab tiuxetan to evaluate a potential benefit. CONCLUSION: Treatment with 90Y ibritumomab tiuxetan induced a clinically relevant CR in a patient with CD20-positive cHL. Thus, we will expand treatment of relapsed CD20-positive HL with 90Y ibritumomab tiuxetan at our institution.

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Publishing Authors By Initials

R Schnell,M Dietlein,K Schomäcker,C Kobe,P Borchmann,H Schicha,M Hallek,A Engert,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Onkologie

VOLUME: 31

Page Numbers: 49-51

Journal Abbreviation:

ISSN: 1423-0240

DAY: 22

MONTH: 01

YEAR: 2008

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7808556

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.

AFFILIATION: Department I of Internal Medicine, University of Cologne, Germany. Roland.Schnell@uni-koeln.de

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Onkologie

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma Related Publications

• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
• Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
• Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
• Control of visually guided behavior by distinct populations of spinal projection neurons.
• Current treatment strategies of the German Hodgkin Study Group (GHSG).
• Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
• Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
• Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons.
• Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
• Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study.
• Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
• Hodgkin's disease. Future treatment strategies: fact or fiction?
• Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells.
• Immunotherapy of Hodgkin's lymphoma.
• K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
• Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
• Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
• [Antibiotic therapy of endocarditis lenta.]
• [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]
• [Thoracic surgery emergencies in early childhood]